CD52 and B-cell chronic lymphocytic leukemia: We previously generated a panel of mAbs capable of targeting hFcγRIIB, showing they enhanced anti-CD20 mAb-mediated depletion of both normal and malignant B cells in vivo, as well as anti-CD52 mAb-mediated depletion of chronic lymphocytic leukemia (CLL) cells (Roghanian et al., 2015).